Last reviewed · How we verify

NCT03601702

EmboTrap ® II Revascularization Device (Neuravi) in Acute Ischemic Stroke

Recruiting now Last updated 16 April 2026
What this trial tests

trial testing Mechanical thrombectomy with EmboTrap ® II Device in Acute Ischemic Stroke in 100 participants. Currently enrolling.

Timeline
1 January 2022
Primary endpoint
31 December 2025
15 June 2027

Quick facts

Lead sponsorNiguarda Hospital
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment100
Start date1 January 2022
Primary completion31 December 2025
Estimated completion15 June 2027
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

Niguarda Hospital

Who can join

18 and older, any sex, with Acute Ischemic Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary aim of Registrap study is to assess the safety and effectiveness of the EmboTrap®II Clot Retriever device (Neuravi) in patients with acute ischemic stroke from large vessel occlusion.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Acute Ischemic Stroke

Currently open trials in the same condition.

Other Niguarda Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03601702.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing